441O A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG). - Neyns, B.; Dirven, I.; Lescrauwaet, L.; Cammaert, M.; Geens, W.; Geeraerts, X.; Stevens, L.; Brock, S.; Kockx, M.; Everaert, H.; Binst, A-M. Van; Tuyaerts, S.; et al. (Annals of Oncology, 2024)